NexGen Energy

Phase A — Understand the business

Company Overview

NexGen Energy Ltd. is a British Columbia-incorporated , Vancouver-headquartered uranium exploration-and-development company, NYSE + TSX + ASX listed under NXE. It was founded in 2011 by Leigh Curyer. It makes zero dollars of revenue today — it is a development-stage issuer whose "product" is a future one: uranium concentrate (U3O8, "yellowcake") from a mine that does not yet exist.

The whole company is essentially one asset: a 100%-owned interest in the Rook I Project, 32 contiguous mineral claims (~35,065 hectares) in the southwestern Athabasca Basin. Inside Rook I sits the Arrow deposit, discovered by NexGen in 2014 — described by third parties as the world's largest undeveloped high-grade uranium deposit.

Business model, plainly. Spend capital for ~15 years (discovery → feasibility → permit → build) with no revenue, funded by serial equity + convertible debt; get the mine permitted and built; then sell U3O8 into a market of nuclear utilities under long-term contracts. Value accrues in three steps — find it (done, 2014), prove + permit it (done, March 2026), build + sell it (starting summer 2026, first production ~2030). NexGen has crossed from step 2 into step 3 this year, which is the single most important fact in this dossier.

Customers. Nuclear utilities. NexGen has already signed offtake contracts totalling 10M+ lbs U3O8 with major US utilities (first 5M lbs in December 2024; doubled to 10M+ via a 5M-lb / 1M-lb-per-year deal with a second US utility in August 2025), all on market-related pricing at delivery — i.e. NexGen keeps upside to the uranium price rather than locking a fixed low price. The research-layer our figures is empty because none of this is revenue yet; these are forward commitments.

Suppliers / contract structure. As a pre-construction developer its "suppliers" are the EPC contractors, drillers, and long-lead equipment vendors it is now procuring for the four-year build. No take-or-pay input contracts of consequence yet.

Competitors. For supply of new Western uranium: Cameco (operating incumbent, Athabasca), Denison Mines (Wheeler River / Phoenix ISR developer, also Athabasca), Uranium Energy Corp (US ISR), Kazatomprom (Kazakh incumbent, ~40% of world mine supply), Paladin/Boss (Africa/Australia). Arrow's differentiator is grade (see Lens 3).

Supply Chain

The KB supply-chain.md for critical-materials is missing on disk, so this is mapped from primary company disclosure + web — named where possible, per the lens rule.

Upstream (into the future mine):

• Drilling / exploration: contract drillers on the Rook I property (2025 drill program ongoing per Q4 disclosure).
• Engineering & procurement (EPC): detailed engineering and procurement is live — C$185.1M of Rook I development spend in FY2025 was "detailed engineering and procurement, and advancement of the 2025 drill program". Wood Canada Limited is a named technical consultant (consent filed as Exhibit 99.12 in the 40-F), alongside independent QPs Simon Allard (P.Eng.), Jason Craven (P.Geo.), Mark Hatton, Mark B. Mathisen (consents Ex-99.9–99.13).
• Regulator (a de facto chokepoint): the Canadian Nuclear Safety Commission (CNSC) — the gate every Canadian uranium mine must pass. This was the binding chokepoint; it cleared March 5, 2026 (Lens 5).

The company: Arrow → planned underground mine + on-site mill producing U3O8 concentrate.

Downstream (out of the future mine):

• Conversion: U3O8 → UF6 (Cameco Port Hope, Ontario; Orano; ConverDyn) — NexGen would sell U3O8 upstream of this, but the conversion bottleneck is part of why utilities want secured pounds.
• Enrichment: Urenco, Orano, Centrus (LEU), Tenex — relevant to end-demand, not NexGen's direct chain.
• End buyers: US nuclear utilities (the named-but-unnamed "major US utilities" on the offtakes). Athabasca location + Canadian sovereignty is a geopolitical selling point for US utilities trying to de-risk away from Russian/Kazakh supply — this is a genuine, durable tailwind (Lens 3).

Chokepoints / single-source dependencies:

1. Single asset. There is no supply-chain diversification — the entire chain converges on one deposit. If Arrow slips, there is no second mine.
2. CNSC permitting — historically the binding constraint; now cleared, which is why the equity re-rated.
3. Skilled labour + long-lead equipment in a remote northern-Saskatchewan build during a global uranium-capex upcycle (Cameco restarts, Denison, others competing for the same contractors).

Verdict on the chain: it is short and concentrated by nature. That is the whole risk and the whole appeal — one high-grade Canadian deposit feeding Western utilities that are structurally short uranium.

Competitive Advantages (moats)

For a developer, "moat" = the deposit's structural quality + the permitting/jurisdiction position rivals can't replicate. NexGen's are unusually strong.

1. Grade — the core moat. Arrow's probable reserves grade 2.37% U3O8 (240 Mlbs); its measured+indicated resource grades 3.10% (357 Mlbs). For context, most global uranium is mined at grades well under 0.5%, and many ISR operations are an order of magnitude lower. High grade → low unit cost: life-of-mine cash cost ~C$13.86/lb, which would place Arrow at the very bottom of the global cost curve — a durable cost moat that survives a lower uranium price.
2. Scale. ~240 Mlbs of probable reserves is a multi-decade, tier-1 resource — the kind of asset that, once producing, is strategically important to Western supply for a generation. This is not a marginal satellite deposit.
3. Jurisdiction + sovereignty premium. Saskatchewan is a top-tier mining jurisdiction; Canada is a trusted supplier to US utilities actively de-risking away from Russian (Tenex) and Kazakh (Kazatomprom) pounds. In a bifurcating uranium market, "Western, non-Russian, non-Kazakh, high-grade" is a real, defensible position.
4. Permitting as a moat, now crystallised. The CNSC Licence to Prepare Site and Construct (issued March 5, 2026) is a barrier no competitor can leapfrog — it took NexGen roughly a decade of environmental assessment, two-part Commission hearings (Nov 2025 + Feb 2026), and provincial approval (Nov 2023) to get here. A permitted, financed, tier-1 Western uranium project is a scarce, non-fungible thing.

Bargaining power. Over customers: rising — utilities are structurally short and are chasing secured Western pounds, and NexGen has held pricing to market-related (upside-retaining) terms rather than fixed. Over suppliers: limited — as a first-time builder competing for scarce EPC/labour in an upcycle, NexGen is a price-taker on construction inputs, which is exactly the vector for cost overruns (Lens 13).

The moat's limit. Every moat here is optionality on a future mine. It is real, but it does not generate a dollar until ~2030 and it is entirely undiversified. The moat protects the value of the deposit; it does not protect the equity from dilution or the uranium price.

Segments

Not applicable — one asset, no revenue, no reportable segments. our figures is an empty header on disk, correctly, because there is nothing to segment. 100% of enterprise valueEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. derives from Rook I / Arrow. Geographic exposure: 100% Saskatchewan, Canada (asset); customer geography = North American utilities (offtake). There is a secondary exploration option — Patterson Corridor East (PCE), where high-grade assays in November 2025 hint at resource-expansion optionality beyond Arrow — but it is early-stage and not in reserves. Treat PCE as a free call option on top of the Arrow base case, not a segment.

---

Phase B — Measure performance

(analyzed as project-development + financing, not earnings-vs-consensus — there are no earnings)

Latest "Result" — the March 2026 permit + FY2025 annual

There is no earnings beat/miss to grade (NexGen is pre-revenue; Q1 2026 reported EPS of −$0.24 vs a −$0.037 "forecast" — a meaningless "miss" driven by non-cash items, financing costs and development accounting, not an operating shortfall ). The lens that matters is the development print:

The defining event — final federal approval, March 5, 2026. The CNSC approved NexGen's Environmental Assessment and issued the Licence to Prepare Site and Construct for the 100%-owned Rook I Project. This followed a two-part Commission hearing (Part 1 on 2025-11-19; Part 2 on 2026-02-09→12) and provincial EA approval (2023-11-09). This is the value-unlocking catalyst — it converts a permitting-risk story into a build-execution story. Management took a Final Investment Decision and set full-scale construction to begin summer 2026, on a four-year build timeline (→ first production ~2030).

Balance sheet — the fuel gauge (the real Phase-B metric):

• Cash > C$1.1B at year-end 2025, after a C$950M global equity raise (Oct 2025) — net proceeds ~C$903.7M; net cash rose ~C$326.0M YoY.
• Debt ~C$488.5M, total liabilities ~C$520.3M, total assets ~C$1.5B, shareholder equity ~C$1.0B.
• Two convertible debentures: 2023 notes US$110M (conversion US$6.76); 2024 notes US$250M (conversion US$10.73). C$29.7M debenture interest paid in FY2025. Note: both conversion strikes are below or near the current ~US$10–11 share price, so both are plausibly in-the-money → they likely convert to equity rather than be repaid in cash (dilutive, but removes a cash-repayment claim).
• FY2025 Rook I development spend: C$185.1M (engineering, procurement, 2025 drilling).
• Shares outstanding: 659,960,072 as of 2025-12-31.

The funding gap — the single most important number. Pre-production capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. is C$2.2B (US$1.58B). Against ~C$1.1B cash, that is a ~C$1.1B financing gap to a fully-funded build — before any cost overrun. This gap is the crux of the bear case (Lens 13) and the most likely source of future dilution.

ICFR / audit flags: disclosure controls concluded effective; no material changes to ICFR in FY2025; auditor KPMG LLP (Vancouver); financials prepared under IFRS (not US GAAP — noted for cross-company comparability).

Earnings Calls (sentiment trend)

transcripts/ is empty on disk (transcripts=0), so this is web-derived and light — labeled accordingly. For a developer, the "call narrative" tracks milestones and financing, not margins:

• Through 2024: narrative = feasibility economics update (capex to C$2.2B, uranium price deck to US$95/lb), first offtakes, "on track for a construction decision."
• Early–mid 2025: narrative = financing sequencing and CNSC contingency planning — a 2025 earnings call reportedly flagged "financing delays, CNSC contingency, and PCE drilling timelines". Tone: preparing capital and permitting in parallel; some market anxiety about the sequencing.
• Late 2025 → Q1 2026: narrative flips decisively to green light — C$950M raise closed (Oct 2025), Part 2 hearing (Feb 2026), licence granted (Mar 2026), FID, summer-2026 construction. Tone: execution/confidence, "shovels in the ground."

Shift over time: from "will they permit + fund it?" (anxious, 2025) → "they're building it" (confident, 2026). The recurring phrases: tier-one, high-grade, elite economics, generational asset, Western supply security. What they've stopped saying: the conditional "if approved." Caveat: transcripts not on the research shelf — sentiment is inferred from secondary coverage, treat as directional.

Comps

Peers pulled from research/companies/_index.json (66 critical-materials names; uranium subset used) plus obvious global uranium names.

Developer-appropriate valuation read (the only honest comp):

• P/NAV: NXE market cap ~US$8.4–8.8B ≈ ~C$11.5–12B, vs updated project after-tax NPV8 ~C$6.3B @ US$95/lb. That is P/NAV ≈ 1.8–1.9× on the base deck. Developers rarely trade above ~1× NAV until producing — so the market is either (a) pricing a higher long-run uranium price than US$95/lb, (b) pricing PCE resource-expansion optionality on top of Arrow, and/or (c) simply exuberant on the scarcity of permitted Western supply. A P/NAV of ~1.9× on a not-yet-built mine is rich and is the number a bear points at first.
• Analyst targets cluster strong-buy: consensus ~C$21–23, range C$16–30, vs a share price in the ~C$15 / ~US$10 area — i.e. the sell-side sees material upside, consistent with a higher-uranium-price NAV.

Do not fabricate the peer multiples. For the pre-revenue names, n/a is the correct entry; for the producers, exact EV/EBITDA per-lb figures were not sourced in this pass and are left n/a rather than invented.

Stock-Price Catalysts (>5% moves, pattern)

NexGen trades as a levered proxy on (a) the uranium price and (b) its own milestone calendar. The >5% movers over recent years:

• Feasibility / economics updates — the March 2021 FS (NPV8 C$3.47B, IRR 52.4%) and the 2024 economics update (capex → C$2.2B, NPV8 → C$6.3B @ US$95/lb).
• Permitting milestones — provincial EA approval (Nov 2023); CNSC hearing dates announced; the Feb 2026 Part-2 hearing and the March 5, 2026 licence were flagged as "the single biggest near-term catalyst".
• Offtake announcements — first 5M lbs (Dec 2024) and the doubling to 10M+ (Aug 2025).
• The C$950M equity raise (Oct 2025) — a large raise is a near-term overhang (dilution) but a medium-term de-risk (funds the build); NXE tends to dip on the raise, recover on the milestone.
• Uranium spot/term price — the dominant macro driver. Spot passed US$100+ in Jan 2026 (up ~25% MoM) then consolidated to ~US$84–87 in Q2 2026; the term price kept climbing to ~US$94 — the highest since 2008. NXE beta to uranium is high.

What the pattern reveals: the market reacts most to (1) the uranium price and (2) binary permitting/financing events — and far less to any income-statement line (there isn't a meaningful one). The 52-week range C$8.68–18.91 shows how violently the stock moves on these swings. This is a momentum + macro instrument, not a cash-flow compounder — yet.

---

Phase C — Judge people & books

Management

CEO — Leigh Curyer (Founder, President & CEO; non-independent director).

1. Track record: Founded NexGen in 2011 and personally drove the 2014 Arrow discovery through to a permitted, financed tier-1 project — a genuinely elite outcome in an industry where most explorers die at the drill bit. Prior: CFO / head of corporate development at Southern Cross Resources (which became Uranium One), and head of corporate development at Accord Nuclear Resource Management, evaluating uranium projects for private-equity firm First Reserve. He is a finance-and-corporate-development operator who has raised >US$1B of equity across North America, Europe and Australia — exactly the skill set a serial-dilution developer needs. He is a capital-markets CEO, not a mine-builder by background — relevant as the company pivots from financing to building (see red flags).
2. Tenure & skin in the game: Founder, ~15 years in the chair. Direct ownership ~0.94% (~C$105.5M) — meaningful in dollar terms, modest in percentage (founder stake diluted by 15 years of raises). Board average tenure ~7.8 yrs, management ~3.3 yrs.
3. Capital allocation: For a pre-revenue developer this = how well they fund the build without destroying per-share value. NexGen has used a layered stack — equity raises + two convertible debentures + strategic ASX listing/A$ raise — and, critically, has timed the big C$950M raise into a strong-uranium/high-share-price window (Oct 2025) ahead of the permit, which is textbook. Downside: 660M shares outstanding reflects heavy cumulative dilution, and ~C$1.1B more is needed.
4. Red flags: Compensation. Total CEO comp reported ~C$13.97M, of which ~93.6% is bonus/stock/options — very high for a company with no revenue, and heavily equity-linked (further dilution + optics risk). Watch for related-party items in the AIF (Exhibit 99.1 to the 40-F — not in the ingested body). No SEC enforcement history (Lens 10).
5. Archetype: Founder-promoter with a capital-markets pedigree — ideal for the discovery-and-permit phase (raise, promote, permit), less obviously the operator you'd hand a C$2.2B remote-Arctic construction project to. The board will likely lean on EPC contractors + a strong project-execution COO/VP-projects layer for the build. Execution-leadership depth is the thing to watch from here.

Forensic Red Flags

Acting as a forensic analyst on a pre-revenue developer, the classic income-statement games (channel stuffing, revenue-recognition tricks) don't apply — there is no revenue. The forensic surface is different and narrower:

• Capitalisation vs expensing: development spend (C$185.1M in FY2025) is capitalised to the Rook I asset — standard for a permitted project, but it means the balance-sheet asset value is a function of management's judgment that the mine will be built and economic. An impairment risk exists if uranium collapses or the build is abandoned (not a fraud flag, a valuation flag).
• Cash burn vs earnings: net loss is dominated by financing costs (C$29.7M debenture interest) and non-cash items; the real forensic question is liquidity/runway, and here the C$1.1B cash vs C$2.2B capex gap is disclosed and stark (Lens 5).
• Dilution mechanics: two convertibles with strikes (US$6.76 / US$10.73) at/below spot → likely equity conversion → built-in dilution that is fully disclosed but easy to under-model. High equity-linked CEO comp adds to the count. This is the biggest "watch the share count" item — legitimate, not deceptive, but material.
• Reserve/resource standard mismatch (disclosed): resources/reserves are reported under Canadian NI 43-101, which "differs significantly from SEC requirements" and "may not be comparable" to US-company disclosure — NexGen states this explicitly in the 40-F. Not a red flag; a comparability caveat US investors must respect.
• Controls / audit: ICFR concluded effective, no material changes, KPMG auditor, dedicated audit committee (Birkett/Veenman/Patricio, Birkett = financial expert). Clean.
• Off-balance-sheet: company states none material.

Regulatory findings (required sub-section).

• SEC Litigation Releases: None. Verified via SEC EDGAR EFTS (LR) for "NexGen Energy," 2021-07-06 → 2026-07-06.
• SEC AAERs: None over the same period.
• Non-SEC enforcement (web): No material FTC/DOJ/FDA/CFPB/consent-decree/fine hits surfaced for NexGen Energy in this pass. The relevant "regulatory" exposure for a uranium miner is permitting/environmental, and that has moved in NexGen's favour (CNSC licence granted, Indigenous/environmental review completed as part of the EA) rather than against it — no adverse enforcement. (Note: uranium projects carry standing environmental/Indigenous-consultation and water-management obligations; none currently manifest as enforcement.)
• 10-K/40-F Item 3 (Legal Proceedings): the ingested 40-F body is the cover/certifications/exhibit list and does not include the Legal Proceedings narrative (that sits in the AIF, Exhibit 99.1, not ingested); no litigation was surfaced via web. Treat as no material litigation identified, with the caveat that the full AIF was not on the shelf.
• Bottom line: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and the ingested 40-F as of 2026-07-06. Auditor and ICFR clean.

---

Phase D — Project & stress-test

Forward Projection

EPS projection is not the right instrument — NexGen will report losses every year until first production (~2030), so a three-year EPS walk would be three years of negative, non-cash-dominated numbers with no signal. The correct forward model for a permitted single-asset developer is the project NPV / production model + the path to it, so that is what I build. labels throughout; inputs sourced where possible.

Project base case (company deck) — the anchor:

• Reserves: 240 Mlbs U3O8 probable @ 2.37%.
• Pre-production capex: C$2.2B (US$1.58B).
• Opex: ~C$13.86/lb LOM cash cost → bottom-of-curve.
• Updated economics @ US$95/lb: after-tax NPV8 ~C$6.3B, IRR ~45%, payback ~12 months. Original FS @ US$50/lb: NPV8 C$3.47B, IRR 52.4%.

Scenario walk on the equity (P/NAV framing):

The value question isn't "what's the mine worth" — it's "who captures it." The mine's asset NPV is real and large; the equity's value depends on (1) the uranium price at production (~2030), (2) how much dilution closes the ~C$1.1B funding gap (every C$1B raised at ~C$15 ≈ ~67M new shares ≈ ~10% dilution ), and (3) whether the build lands on-budget (uranium projects have a poor overrun record; capex already went C$1.3B→C$2.2B).

No Brier forecast logged — per the --watchlist rule (skip our model create in the unattended loop; a base case is committed only inside our position log). The natural tracked forecast, when promoted, is binary: "NexGen pours first U3O8 by 2030-12-31" and/or "Rook I initial capex comes in ≤ C$2.6B (≤~18% over the C$2.2B budget)."

Bull vs Bear

Bull case. NexGen owns a permitted, financed-to-C$1.1B, tier-1, bottom-of-cost-curve Western uranium deposit at the exact moment the uranium market is entering a structural, multi-decade deficit (Sprott projects a ~197M-lb deficit by 2040; the EIA warns US utilities face a ~184M-lb shortfall over the next decade ). Term prices are at 2008 highs (~US$94) and rising, utilities are contracting below replacement and must catch up, and AI-datacenter power demand is a fresh, credible incremental leg for nuclear. Arrow is one of the very few new Western pounds that can actually reach market this decade, it retains uranium-price upside on its offtakes, and it has resource-expansion optionality at PCE on top. The March 2026 permit removed the single biggest binary risk. The market that priced this as a maybe-mine is re-rating it toward a will-be-mine, and a higher long-run uranium deck than the base US$95/lb would send NAV — and the stock — materially higher.

Bear case (things that could permanently impair the equity, not just dent a quarter).

1. The uranium price is the whole thing, and it's cyclical. Uranium is a boom-bust commodity with a graveyard of developers that got permitted into the top of a cycle and produced into the bottom. If spot mean-reverts toward US$60 and the deficit narrative slips (SMR delays, a reactor-demand disappointment, a Kazakh/Sprott-selling supply shock), NAV compresses and the funding gap becomes punishing — the double-hit.
2. ~C$1.1B funding gap + a four-year build = dilution and overrun risk. Capex already climbed C$1.3B → C$2.2B; the sector's history of remote-project cost blowouts is dreadful. A move to C$2.8–3.0B, funded by equity at a lower share price, is the canonical way this equity halves without the deposit changing at all.
3. Single-asset, no cash flow, no room for error. Any construction/technical/labour setback has no revenue and no second mine to absorb it — it goes straight to the raise.

Pre-mortem (it's Jan 2028, thesis broke — what happened?). Uranium spot faded from ~US$90 to ~US$65 through 2027 as utility contracting disappointed and a large producer (Kazatomprom restart / Sprott redemption) added supply; simultaneously Rook I construction hit a labour-and-long-lead-equipment wall and management guided capex up ~20–25%. NexGen returned to market for ~C$1.5B of equity at a depressed price, the convertibles converted, share count ballooned toward ~900M+, and the stock re-rated from ~1.9× NAV to ~1× on a lower NAV — a ~50%+ drawdown with the deposit itself completely intact. Nothing about the geology broke; the equity broke on price + dilution + time.

Are multiples too high? On the base US$95/lb deck, yes — ~1.9× P/NAV on a pre-production mine is demanding. It is only "cheap" if you underwrite a structurally higher long-run uranium price (US$110–130+) and a clean, on-budget build. That is a legitimate view, but it is a view on two things going right, not a margin of safety.

Contrarian view (what the market is refusing to see). Two-sided. Bulls' blind spot: the time-and-dilution cost between here and 2030 — permitting risk is gone, but execution + financing risk is only just beginning, and the stock already prices success. Bears' blind spot: Western permitted supply is genuinely scarce and strategically defensible — if the AI-power/nuclear-renaissance demand thesis is even half right, a permitted 240-Mlb Athabasca mine is a national-security-grade asset that could command a strategic premium (utility prepay, government backstop, or takeover by a Cameco/Orano/sovereign buyer) that pure P/NAV math misses entirely. NexGen is more likely than most developers to be acquired before it ever finishes building — that optionality is under-modeled.

Devil's Advocate (short-seller)

Dismantling the bull case:

• Where the money is made can't break structurally — because it isn't being made yet. The entire thesis is a 2030 call option financed by dilution. A short-seller's cleanest attack is time + capital: you are paying ~C$12B today for a ~C$6.3B (base-deck) NPV that starts producing in four years and needs another ~C$1.1B (minimum) of capital first. Value destruction doesn't require the mine to fail — it just requires the uranium price to be ordinary and the raise to be big.
• Revenue concentration = 100% one deposit, one commodity, one price. There is no diversification anywhere. If the uranium price disappoints by 20–30%, the base-deck NPV drops from ~C$6.3B toward ~C$3.5–4B — below today's market cap — and the stock has to fall to re-rate to a sane P/NAV even before factoring the funding-gap dilution.
• The moat is weaker than bulls think in exactly one way: it doesn't protect the equity. Grade and permit protect the asset's value; they do nothing for the share count or the entry price. Bulls conflate "great deposit" with "great stock at this price."
• Most dangerous competitor bulls underestimate: the incumbent supply itself. Not a rival developer — Kazatomprom's ability to flex low-cost pounds and Cameco's idled capacity (McArthur River/Cigar Lake ramp) can cap the uranium price precisely when NexGen needs it high. The bear on NexGen is fundamentally a bear on the uranium price, and the low-cost incumbents are the ceiling.
• Capital-allocation / incentives: ~94%-variable CEO comp of ~C$14M at a no-revenue company, funded ultimately by shareholder dilution, is a governance smell — it rewards share-price/promotion, and the convertibles' low strikes mean insiders and note-holders are positioned for equity upside while common holders wear the dilution.
• Assumptions that must hold for today's price: (1) long-run uranium ≥ ~US$95/lb, ideally higher; (2) capex holds ~C$2.2B (±modest); (3) the ~C$1.1B gap is closed without a punishing down-round; (4) construction finishes ~on time to ~2030; (5) no macro/uranium shock in the four-year window. Break any one and the ~1.9× P/NAV is untenable.
• The single scenario that permanently impairs: a uranium bear market (US$50–60/lb) arriving mid-construction — forcing a large equity raise at a low price into a falling NAV. Plausibility: moderate. Uranium has done exactly this repeatedly; the deficit thesis is real but the timing of a four-year build against a cyclical price is the exposure. It doesn't kill the deposit; it can halve the equity.

Management Questions (ordered by information value)

1. Financing the gap: With ~C$1.1B cash against ~C$2.2B pre-production capex, what is the exact funding plan for the remaining ~C$1.1B+ — equity, debt, strategic/utility prepay, government (e.g. Canadian/EDC or US DOE) support — and what is the maximum further equity dilution common holders should model?
2. Capex confidence: Capex went C$1.3B → C$2.2B. What is the contingency inside the C$2.2B, how much of the C$2.2B is fixed-price/locked via signed EPC and long-lead orders today, and what would move it again?
3. Uranium-price sensitivity of the decision: At what long-run realized uranium price does Rook I's equity value (post-dilution) stop making sense, and how much of the offtake book is market-linked vs floor-protected if spot falls during the build?
4. Execution leadership: Who owns delivery of a C$2.2B remote-Saskatchewan build day-to-day — what is the project-execution team's track record building a mine of this scale, and how is that separate from the corporate/capital-markets team?
5. Schedule risk: What are the top three critical-path items for the four-year build (labour, long-lead equipment, tailings/water infrastructure), and what is the realistic P50 vs P90 first-production date?
6. Convertibles: Do you expect the 2023 (US$6.76) and 2024 (US$10.73) debentures to convert to equity, and how does that change the fully-diluted share count you plan against?
7. Offtake economics: What average realized price and volume can shareholders expect from the ~10M lbs contracted, and what share of first-decade production is already committed vs open to spot?
8. PCE optionality: How material could Patterson Corridor East be to reserves/mine life, and would developing it require new capital or ride on Rook I infrastructure?
9. Takeover posture: Given the scarcity of permitted Western supply, has the board defined its stance on a strategic/utility/sovereign acquisition, and what does it view as fair value per lb in the ground?
10. Labour & community: What are the binding Indigenous-partnership and northern-labour commitments, and could any become a schedule or cost constraint during construction?
11. Cost curve durability: How resilient is the ~C$13.86/lb cash-cost estimate to Saskatchewan power, diesel, reagent and labour inflation over a four-year build and multi-decade life?
12. Balance-sheet sequencing: Will you pre-fund the entire build before committing, or fund in tranches against milestones — and what covenant/leverage limits will you accept?
13. Governance/comp: How does the board justify ~94%-variable, ~C$14M CEO compensation at a pre-revenue issuer, and how is it tied to per-share (not just absolute) value creation through the build?
14. Downside plan: If uranium falls to US$60/lb mid-construction, what is the contingency — slow the build, raise more, partner, or pause — and at what trigger?
15. Reporting standard: For US investors, can you bridge the NI 43-101 reserve/resource figures to what they'd look like under SEC S-K 1300, so the "not comparable" caveat is quantified?

---